15 companies had initial public offerings and raised $6.4 billion this week, making it the most active week in the IPO market since 2007. Including deals that priced yesterday and began trading today, July saw 34 IPOs, a post-tech bubble record....read more
Loxo Oncology, an early-stage biotech developing targeted therapies to treat solid tumors, raised $68 million by offering 5.3 million shares (vs. 4.4 million originally planned) at $13, the midpoint of the $12 to $14 range. Loxo Oncology will list on the NASDAQ...read more
As the IPO market prepares for the busiest week of the year, we see a broad spectrum of IPOs, including LBOs, high-growth plays, energy spinoffs and financial firms, all of which could be outnumbered by a wave of biotechs. IPO performance has stabilized after it...read more
Loxo Oncology, a biotech developing small molecule therapeutics to treat solid tumors, announced terms for its IPO on Monday. The Stamford, CT-based company plans to raise $57 million by offering 4.4 million shares at a price range of $12 to $14. At the midpoint...read more
US IPO Pricing Recap: 15 IPOs in the most active week since 2007; 66% ended at or below IPO price
15 companies had initial public offerings and raised $6.4 billion this week, making it the most active week in the IPO market since 2007. Including deals that priced yesterday and began trading today, July saw 34 IPOs, a post-tech bubble record....read more
Loxo Oncology prices upsized IPO at $13, the midpoint of the range
Loxo Oncology, an early-stage biotech developing targeted therapies to treat solid tumors, raised $68 million by offering 5.3 million shares (vs. 4.4 million originally planned) at $13, the midpoint of the $12 to $14 range. Loxo Oncology will list on the NASDAQ...read more
22 US IPOs planned for the week of Jul 28
As the IPO market prepares for the busiest week of the year, we see a broad spectrum of IPOs, including LBOs, high-growth plays, energy spinoffs and financial firms, all of which could be outnumbered by a wave of biotechs. IPO performance has stabilized after it...read more
Cancer biotech Loxo Oncology sets terms for $57 million IPO
Loxo Oncology, a biotech developing small molecule therapeutics to treat solid tumors, announced terms for its IPO on Monday. The Stamford, CT-based company plans to raise $57 million by offering 4.4 million shares at a price range of $12 to $14. At the midpoint...read more